Cargando…
A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy
The Oxford-AstraZeneca ChAdOx1 nCoV-19 is a vaccine against the COVID-19 infection that was granted a conditional marketing authorization by the European Commission in January 2021. However, following a report from the Pharmacovigilance Risk Assessment Committee (PRAC) of European Medicines Agency,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229711/ https://www.ncbi.nlm.nih.gov/pubmed/34201330 http://dx.doi.org/10.3390/vaccines9060618 |
_version_ | 1783713042083610624 |
---|---|
author | Palladino, Raffaele Ceriotti, Daniele De Ambrosi, Damiano De Vito, Marta Farsoni, Marco Seminara, Giuseppina Barone-Adesi, Francesco |
author_facet | Palladino, Raffaele Ceriotti, Daniele De Ambrosi, Damiano De Vito, Marta Farsoni, Marco Seminara, Giuseppina Barone-Adesi, Francesco |
author_sort | Palladino, Raffaele |
collection | PubMed |
description | The Oxford-AstraZeneca ChAdOx1 nCoV-19 is a vaccine against the COVID-19 infection that was granted a conditional marketing authorization by the European Commission in January 2021. However, following a report from the Pharmacovigilance Risk Assessment Committee (PRAC) of European Medicines Agency, which reported an association with thrombo-embolic events (TEE), in particular disseminated intravascular coagulation (DIC) and cerebral venous sinus thrombosis (CVST), many European countries either limited it to individuals older than 55–60 years or suspended its use. We used publicly available data to carry out a quantitative benefit–risk analysis of the vaccine among people under 60 in Italy. Specifically, we used data from PRAC, Eudravigilance and ECDC to estimate the excess number of deaths for TEE, DIC and CVST expected in vaccine users, stratified by age groups. We then used data from the National Institute of Health to calculate age-specific COVID-19 mortality rates in Italy. Preventable deaths were calculated assuming a 72% vaccine efficacy over an eight-month period. Finally, the benefit–risk ratio of ChAdOx1 nCoV-19 vaccination was calculated as the ratio of preventable COVID-19 deaths to vaccine-related deaths, using Monte-Carlo simulations. We found that among subjects aged 20–29 years the benefit–risk (B-R) ratio was not clearly favorable (0.70; 95% Uncertainty Interval (UI): 0.27–2.11). However, in the other age groups the benefits of vaccination largely exceeded the risks (for age 30–49, B-R ratio: 22.9: 95%UI: 10.1–186.4). For age 50–59, B-R ratio: 1577.1: 95%UI: 1176.9–2121.5). Although many countries have limited the use of the ChAdOx1 nCoV-19 vaccine, the benefits of using this vaccine clearly outweigh the risks in people older than 30 years. Study limitations included risk of underreporting and that we did not provide age-specific estimates. The use of this vaccine should be a strategic and fundamental part of the immunization campaign considering its safety and efficacy in preventing COVID-19 and its complications. |
format | Online Article Text |
id | pubmed-8229711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82297112021-06-26 A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy Palladino, Raffaele Ceriotti, Daniele De Ambrosi, Damiano De Vito, Marta Farsoni, Marco Seminara, Giuseppina Barone-Adesi, Francesco Vaccines (Basel) Article The Oxford-AstraZeneca ChAdOx1 nCoV-19 is a vaccine against the COVID-19 infection that was granted a conditional marketing authorization by the European Commission in January 2021. However, following a report from the Pharmacovigilance Risk Assessment Committee (PRAC) of European Medicines Agency, which reported an association with thrombo-embolic events (TEE), in particular disseminated intravascular coagulation (DIC) and cerebral venous sinus thrombosis (CVST), many European countries either limited it to individuals older than 55–60 years or suspended its use. We used publicly available data to carry out a quantitative benefit–risk analysis of the vaccine among people under 60 in Italy. Specifically, we used data from PRAC, Eudravigilance and ECDC to estimate the excess number of deaths for TEE, DIC and CVST expected in vaccine users, stratified by age groups. We then used data from the National Institute of Health to calculate age-specific COVID-19 mortality rates in Italy. Preventable deaths were calculated assuming a 72% vaccine efficacy over an eight-month period. Finally, the benefit–risk ratio of ChAdOx1 nCoV-19 vaccination was calculated as the ratio of preventable COVID-19 deaths to vaccine-related deaths, using Monte-Carlo simulations. We found that among subjects aged 20–29 years the benefit–risk (B-R) ratio was not clearly favorable (0.70; 95% Uncertainty Interval (UI): 0.27–2.11). However, in the other age groups the benefits of vaccination largely exceeded the risks (for age 30–49, B-R ratio: 22.9: 95%UI: 10.1–186.4). For age 50–59, B-R ratio: 1577.1: 95%UI: 1176.9–2121.5). Although many countries have limited the use of the ChAdOx1 nCoV-19 vaccine, the benefits of using this vaccine clearly outweigh the risks in people older than 30 years. Study limitations included risk of underreporting and that we did not provide age-specific estimates. The use of this vaccine should be a strategic and fundamental part of the immunization campaign considering its safety and efficacy in preventing COVID-19 and its complications. MDPI 2021-06-08 /pmc/articles/PMC8229711/ /pubmed/34201330 http://dx.doi.org/10.3390/vaccines9060618 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Palladino, Raffaele Ceriotti, Daniele De Ambrosi, Damiano De Vito, Marta Farsoni, Marco Seminara, Giuseppina Barone-Adesi, Francesco A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy |
title | A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy |
title_full | A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy |
title_fullStr | A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy |
title_full_unstemmed | A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy |
title_short | A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy |
title_sort | quantitative benefit–risk analysis of chadox1 ncov-19 vaccine among people under 60 in italy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229711/ https://www.ncbi.nlm.nih.gov/pubmed/34201330 http://dx.doi.org/10.3390/vaccines9060618 |
work_keys_str_mv | AT palladinoraffaele aquantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT ceriottidaniele aquantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT deambrosidamiano aquantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT devitomarta aquantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT farsonimarco aquantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT seminaragiuseppina aquantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT baroneadesifrancesco aquantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT palladinoraffaele quantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT ceriottidaniele quantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT deambrosidamiano quantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT devitomarta quantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT farsonimarco quantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT seminaragiuseppina quantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly AT baroneadesifrancesco quantitativebenefitriskanalysisofchadox1ncov19vaccineamongpeopleunder60initaly |